RxDoctor Payments DataLook up a doctor →

Hemal Gada, MD

Cardiovascular Disease · Wormleysburg, PANPI 1386852390

Payments from drug & device makers

$6,697,994in general payments, 2019–2025

Across 2,751 payments — averaging $2434.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4.5M
  • Edwards Lifesciences$1.2M
  • Boston Scientific$508K
  • Abbott$322K
  • Daiichi Sankyo Inc.$21K
  • Bard Peripheral Vascular, Inc.$18K
  • plus $44K from 13 others
$281in research payments, 2019–2025

Across 1 payment — averaging $281.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$281

What the payments were for

  • Consulting fees$125,6667%
  • Speaking & faculty fees$1,429,18379%
  • Grants$890%
  • Travel & lodging$192,91911%
  • Food & beverage$41,0792%
  • Education$12,0311%
  • Other$2820%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,697,994 in reported general payments places this provider in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$211,807
Medicare patients
374
Services billed
872

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin98$78,665
EliquisApixaban87$60,887
EntrestoSacubitril/Valsartan27$21,358
Metoprolol Succinate102$1,731
Atorvastatin Calcium76$689
Metoprolol Tartrate69$610
Rosuvastatin Calcium15$527
Warfarin Sodium41$516
ClopidogrelClopidogrel Bisulfate47$393
JantovenWarfarin Sodium20$366
Amlodipine Besylate47$354
Furosemide85$177
Amiodarone Hcl11$129
Hydrochlorothiazide14$124
Spironolactone20$101

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Wormleysburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →